The stock of NovaBay Pharmaceuticals, Inc. (NYSE:NBY) is now priced at $0.94 and the shares are 0.04 points up or 4.13% higher compared to its previous closing price of $0.9. The stock had 4.018 million contracts set over the past session. NBY shares’ daily volume is compared to its average trading volume at 6.252 million shares. However, it has a float of 32.52 million and although its performance was -2.68% over the week, it’s one to watch. It means the stock’s downside potential is -100% with the NBY share price recently placing at $0.88 to $1.05. However, some brokerage firms have priced the stock below the average, including one that has called $1.75.
The shorts are running away from the NovaBay Pharmaceuticals, Inc. stock, with the latest data on short interest released on July 31, 2020, showing that short interest numbers in the NBY shares have declined. Short interest in the stock represents just 1.68% of its float, but the volume has dropped by 0.
In the last trading session, NovaBay Pharmaceuticals, Inc. (NYSE:NBY) dropped by -$0.0258 over the week and lost -$0.2928 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $1.94. The stock recorded its established 52-week high on 07/13/20.
Since 03/16/20, the stock has traded to a low of $0.24 at 290.5%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 3.54. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.
Looking at current readings, NovaBay Pharmaceuticals, Inc.’s two-week RSI is 41.86. This suggests that the stock is neutral at the moment and that NBY shares’ price movement remains stable. The stochastic readings are equally revealing at 8.18% meaning the NBY share price is currently in overbought territory.
The technical chart shows that the NBY stock will likely settle at between $1.0315 and $1.1257 per share. However, if the stock dips below $0.8615, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $0.7857.
Currently, the stock is trading in the red of MACD, with a reading of -0.0464. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.
The average rating for the NBY equity is 1.5 and is currently gathering a bullish momentum. Of 2 analysts tracking NovaBay Pharmaceuticals, Inc. polled by Reuters, 0 rated NBY as a hold. The remaining 2 analysts were split evenly. However, the split wasn’t equal as a majority (2) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.
Zacks Consensus Estimate forecasts that the current-quarter revenues for NovaBay Pharmaceuticals, Inc. (NYSE:NBY) will decrease by about -99.94%, which will see them reach $2.52 million. The company’s full-year revenues are, however, expected to increase by about 72.12%, up from $6.6 million to $11.36 million. NBY’s expected adjusted earnings should surge almost 300% to end up at -$0.04 per share, while for the fiscal year, analysts project the company’s earnings to drop by about -47.92% to record -$0.25/share.